Aptar CSP Technologies, part of Aptar Group, has announced a new manufacturing site able to produce its Activ-Blister solutions for oral slide dose drugs in Europe. The move is part of a key strategic effort to expand the production of Activ-Blister technology globally and results from a 3-way collaboration between Aptar CSP, Uhlmann, and Ivers-Lee (a local contract manufacturing organization).
The collaboration consists of a fully automated Uhlmann blister machine validated to package oral solid dose drug products with Activ-Blister solutions heat-staked to the foil at a rate of up to 250 blisters per minute. The equipment is designed to integrate Activ-Blister technology into the blister cavity with precision placement. The equipment has been fully validated and is in place at Ivers-Lee, a CMO capable of manufacturing Activ-Blister solutions from R&D to commercialization. A CMO in EMEA will support regional customers and ensure speed-to-market.
“Expanding global manufacturing sites for Activ-Blister technology reflects our commitment to delivering global access to innovative active material science solutions for patients and consumers,” said Badre Hammond, VP commercial operations and GM APAC, Aptar CSP Technologies. “With manufacturing capabilities now available in both the US and EMEA, we will turn our attention to bringing production of this technology to the Asia market.”
Activ-Blister Solutions integrates Aptar CSP’s proprietary 3-Phase Activ-Polymer platform technology into individual blister cavities to provide precision microclimate protection for sensitive drug products. This technology can be customized specifically for the drug developer’s formulation to provide a broad spectrum of specific drug protection including moisture adsorption, and oxygen and odor scavenging. The technology can also scavenge volatile organic compounds (VOCs) and emit aromas.
